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Summary
Background Millions of HIV-infected people worldwide receive antiretroviral therapy (ART) in programmes using 
WHO-recommended standardised regimens. Recent WHO guidelines recommend a boosted protease inhibitor plus 
raltegravir as an alternative second-line combination. We assessed whether this treatment option offers any advantage 
over the standard protease inhibitor plus two nucleoside reverse-transcriptase inhibitors (NRTIs) second-line 
combination after 144 weeks of follow-up in typical programme settings.
Methods We analysed the 144-week outcomes at the completion of the EARNEST trial, a randomised controlled trial 
done in HIV-infected adults or adolescents in 14 sites in five sub-Saharan African countries (Uganda, Zimbabwe, 
Malawi, Kenya, Zambia). Participants were those who were no longer responding to non-NRTI-based first-line ART, 
as assessed with WHO criteria, confirmed by viral-load testing. Participants were randomly assigned to receive a 
ritonavir-boosted protease inhibitor (lopinavir 400 mg with ritonavir 100 mg, twice per day) plus two or three clinician-
selected NRTIs (protease inhibitor plus NRTI group), protease inhibitor plus raltegravir (400 mg twice per day; 
protease inhibitor plus raltegravir group), or protease inhibitor monotherapy (plus raltegravir induction for first 
12 weeks, re-intensified to combination therapy after week 96; protease inhibitor monotherapy group). Randomisation 
was by computer-generated randomisation sequence, with variable block size. The primary outcome was viral load of 
less than 400 copies per mL at week 144, for which we assessed non-inferiority with a one-sided α of 0·025, and 
superiority with a two-sided α of 0·025. The EARNEST trial is registered with ISRCTN, number 37737787.
Findings Between April 12, 2010, and April 29, 2011, 1837 patients were screened for eligibility, of whom 1277 patients 
were randomly assigned to an intervention group. In the primary (complete-case) analysis at 144 weeks, 317 (86%) of 
367 in the protease inhibitor plus NRTI group had viral loads of less than 400 copies per mL compared with 312 (81%) 
of 383 in the protease inhibitor plus raltegravir group (p=0·07; lower 95% confidence limit for difference 10·2% vs 
specified non-inferiority margin 10%). In the protease inhibitor monotherapy group, 292 (78%) of 375 had viral loads 
of less than 400 copies per mL; p=0·003 versus the protease inhibitor plus NRTI group at 144 weeks. There was no 
difference between groups in serious adverse events, grade 3 or 4 adverse events (total or ART-related), or events that 
resulted in treatment modification.
Interpretation Protease inhibitor plus raltegravir offered no advantage over protease inhibitor plus NRTI in virological 
efficacy or safety. In the primary analysis, protease inhibitor plus raltegravir did not meet non-inferiority criteria. 
A regimen of protease inhibitor with NRTIs remains the best standardised second-line regimen for use in programmes 
in resource-limited settings.
Funding European and Developing Countries Clinical Trials Partnership (EDCTP), UK Medical Research Council, 
Instituto de Salud Carlos III, Irish Aid, Swedish International Development Cooperation Agency, Instituto Superiore 
di Sanita, Merck, ViiV Healthcare, WHO.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Over 17 million people currently receive antiretroviral 
therapy (ART) for HIV infection worldwide, most of whom 
live in resource-limited settings. ART is usually delivered 
using the WHO-recommended public health approach, 
characterised by use of standardised sequential regimens 
and simplified monitoring and care.1 WHO-recommended 
standardised second-line therapy comprises two nucleo-
side reverse-transcriptase inhibitors (NRTIs) combined 
with a boosted protease inhibitor.2
There are theoretical reasons why replacing the NRTIs 
with raltegravir in second-line therapy might be 
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advantageous, primarily the absence of cross-resistance to 
first-line therapy. Three randomised controlled trials3–5 have 
evaluated the combination of a protease inhibitor with 
raltegravir and did not show a benefit over standard 
protease inhibitor plus NRTI regimens after 48–96 weeks 
of follow-up, although all trials reported virological non-
inferiority over this duration. Protease inhibitor plus 
raltegravir is included as an alternative regimen in the 
2016 WHO treatment guidelines (with ritonavir-boosted 
lopinavir as the protease inhibitor).2 However, before 
changing the standardised WHO second-line regimens in 
large-scale treatment programmes, it is essential to evaluate 
the durability of this combination over a longer period than 
48–96 weeks, and to investigate whether there are specific 
patient groups in which it has advantages or disadvantages.
Here, we report outcomes after 144 weeks of follow-up 
from the EARNEST trial, the largest of the trials assessing 
protease inhibitor plus raltegravir and the only trial with 
follow-up beyond 96 weeks, and examine its performance 
in subgroups relevant for resource-limited settings. We 
also report outcomes after reintroduction of NRTIs after 
an initial period of protease inhibitor monotherapy as 
second-line treatment.
Methods
Study design and participants
The EARNEST trial was a randomised controlled trial 
done in 14 sites in five sub-Saharan African countries 
(Uganda, Zimbabwe, Malawi, Kenya, and Zambia). 
Eligible patients were HIV-infected adults or adolescents 
older than 12 years who were no longer responding to a 
first-line combination of NRTIs with a non-NRTI (based 
on WHO clinical, immunological, or virological criteria; all 
confirmed by viral load of >400 copies per mL).3 Exclusion 
criteria were pregnancy or breastfeeding, life expectancy of 
less than 1 month, contraindications to any of the 
study drugs, ongoing requirement for treatment with 
concomitant drugs with known interaction with any study 
drug, or known hepatitis B surface antigen positivity.
The protocol was approved by ethics committees in all 
participating countries and the UK. All participants (and 
caregivers of adolescents younger than 18 years) provided 
written informed consent.
Randomisation and masking
Patients were randomly assigned (1:1:1) to one of three 
treatment groups. Randomisation was stratified by 
centre, and screening CD4 count (<200 cells per µL vs 
≥200 cells per µL). The computer-generated, sequentially 
numbered randomisation list (variable block sizes) was 
preprepared by the trial statistician and incorporated in 
the online secure database. Random isation was done by 
the trial manager at each centre, who could access the 
next number, but not the whole list. Treatment was given 
open-label (ie, patients and investigators were not 
blinded to treatment allocation).
Procedures
Patients were randomly assigned a ritonavir-boosted 
protease inhibitor (standardised to lopinavir 400 mg and 
Research in context
Evidence before this study
We searched PubMed using terms including “second-line 
therapy”, “protease inhibitors”, and the individual drug 
names, and reviewed relevant HIV conference abstracts to 
identify clinical trials done in patients who had failed on a 
first-line non-nucleoside reverse-transcriptase inhibitor 
(NNRTI)-based combination, which compared the 
standard-of-care protease inhibitor plus NRTI combination 
for second-line therapy with either a protease inhibitor plus 
raltegravir combination or with protease inhibitor 
monotherapy. No language or date restrictions were used. 
No relevant studies were identified in our initial search on 
March 1, 2009. An updated search on June 1, 2017, using the 
same terms, identified three published randomised 
controlled trials reporting outcomes after 48 or 96 weeks’ 
treatment with the protease inhibitor plus raltegravir 
combination (including the earlier report from this trial) 
that concluded that this option was non-inferior, and 
two randomised controlled trials reporting outcomes after 
48 or 96 weeks’ treatment with protease inhibitor 
monotherapy (including the earlier report from this trial), 
which concluded that this option was inferior to standard 
of care.
Added value of this study
This trial provides the first comparative, randomised data on 
long-term (144 weeks) outcomes with the protease inhibitor plus 
raltegravir regimen in second-line therapy. With this longer 
duration of follow-up, we found that non-inferiority was not 
consistently demonstrated across all analyses, and there was no 
evidence of a safety benefit with the protease inhibitor plus 
raltegravir regimen compared with the standard-of-care protease 
inhibitor plus NRTI combination. The trial also confirms that the 
initial response of the protease inhibitor plus NRTI regimen is 
durable with longer-term follow-up and that reintroduction of 
combination therapy restores virological suppression after 
prolonged protease inhibitor monotherapy, emphasising the 
contribution of NRTIs to second-line regimen activity.
Implications of all the available evidence
Taking into account the higher cost of raltegravir, the absence of 
clear advantages of protease inhibitor plus raltegravir seen in any 
trial and the failure to show non-inferiority consistently across all 
analyses after 144 weeks of treatment in this trial suggest that 
there is no compelling reason for national programmes to adopt 
this combination as the standardised second-line therapy in the 
public health approach to antiretroviral therapy.
See Online for appendix
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ritonavir 100 mg, both taken twice per day) plus two 
NRTIs (protease inhibitor plus NRTI group), plus 
raltegravir 400mg twice per day (protease inhibitor plus 
raltegravir group), or alone as monotherapy (after an 
initial 12-week raltegravir induction; protease inhibitor 
monotherapy group) and were followed up for 144 weeks. 
In the protease inhibitor plus NRTI group, NRTIs were 
selected by the physician without resistance testing, 
following WHO algorithms (switch to tenofovir if 
previously on stavudine or zidovudine, and vice versa) 
and taking into account side-effects on first-line, local 
standard-of-care, and local drug availability. The protocol 
initially allowed treatment with three NRTIs in Malawi 
(reduced to two NRTIs later when local guidelines 
changed). After a data monitoring committee (DMC) 
recommendation based on poorer viral-load suppression 
and more protease inhibitor resistance in the protease 
inhibitor monotherapy group than in the protease inhibitor 
plus NRTI group, patients in the protease inhibitor mono -
therapy group were switched to combination therapy 
(usually by reintro ducing NRTIs) after May, 2013 
(all patients had completed at least 96 weeks of follow-up 
after randomisation).
Patients were assessed every 4–8 weeks, with most 
visits done by nurses. Adherence was assessed at each 
visit through structured questions, with intensive 
adherence counselling when lapses were identified. 
Treatment was monitored clinically, with full blood 
count, alanine transaminase, serum creatinine, and 
urine dipstick tests for glucose, protein, and leucocytes 
done at weeks 12, 48, 96, and 144 after randomisation, 
and CD4 cell counts every 12–16 weeks in the local 
site’s laboratory. Additional tests were permitted at the 
discretion of the treating clinician to evaluate and 
monitor incident adverse events. Within-class ART 
substitutions were allowed for toxicity or poor 
tolerability. There was no real-time viral-load 
monitoring, but if a patient developed clinical or 
immunological failure (definitions as for trial entry), 
and an alternative regimen was available locally, sites 
could do open local viral-load testing (and subsequent 
resistance testing, if it would affect drug selection) 
after approval from a clinical expert review committee 
(CERC) and change treatment if needed. In the 
protease inhibitor monotherapy group, after the 
recommendation by the DMC to reintroduce 
combination treatment, all trial viral-load and 
resistance testing results were provided to the treating 
clinicians who were permitted to additionally test for 
viral load and resistance in these patients at their 
discretion. Women assigned protease inhibitor 
monotherapy who became pregnant added NRTIs 
while pregnant or breastfeeding. Tuberculosis was 
treated using rifabutin, with ART unchanged.
During the trial, viral load was measured centrally 
(Joint Clinical Research Centre [JCRC], Kampala, 
Uganda) in batches of samples stored at weeks 48 and 
96 using the Abbott RealTime HIV-1 assay (Abbott 
Laboratories, IL, USA); individuals who did the assays 
were blinded to randomised allocation. After trial closure, 
viral-load testing was done on samples stored at weeks 4, 
12, 24, 36, 64, 80, 110, 126, and 144 (for protease inhibitor 
monotherapy, intermediate timepoints were tested 
systematically to week 48 only). Genotyping (reverse 
transcriptase, protease, and integrase, according to 
group) was done blinded on all post-randomisation 
samples with viral load of more than 1000 copies per mL 
at Janssen Diagnostics (Beerse, Belgium). Genotyping 
(reverse transcriptase) of baseline samples from patients 
in the protease inhibitor plus NRTI group and protease 
inhibitor plus raltegravir group was done at the JCRC 
(Kampala). Drug susceptibility prediction used the 
Stanford algorithm (version 7). Subtype was determined 
using REGA (version 3.0). Viral loads and genotypes 
were reviewed by the DMC, but not provided to treating 
clinicians during the trial (with the exception of relevant 
viral load and genotypes from protease inhibitor 
monotherapy group after the decision to reintensify 
therapy).
Figure 1: Trial profile
NRTIs=nucleoside reverse-transcriptase inhibitors. PI=protease inhibitor.
1277 randomly assigned
1837 participants screened for eligibility
560 excluded 
396 had viral load <400 copies per mL
68 had viral load <5000 copies per mL and 
no other immunological or clinical failure
21 ineligible for other reasons
3 had poor adherence
9 were pregnant or breastfeeding
7 had renal, hepatic, or other disease
2 required incompatible drugs
75 not randomly assigned for other reasons
33 died or switched before randomisation 
or were too sick to participate
40 did not consent or return
2 were not randomly assigned because 
enrolment closed
42 died before week 144
10 withdrew or were lost to 
follow-up before week 144
374 followed up at week 144
7 missing viral load
33 died before week 144
11 withdrew or were lost to 
follow-up before week 144
389 followed up at week 144
6 missing viral load
31 died before week 144
9 withdrew or were lost to 
follow-up before week 144
378 followed up at week 144
3 missing viral load
418 were assigned to receive PI
monotherapy with a
12 week PI plus raltegravir
induction
367 included in primary
viral-load analysis
383 included in primary
viral-load analysis
375 included in primary
viral-load analysis
433 were assigned to receive PI
plus raltegravir
426 were assigned to receive
standard-of-care PI plus two 
or three NRTIs
For the Stanford University HIV 
drug resistance database see 
http://hivdb.stanford.edu
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Neurocognitive function and peripheral neuropathy 
were assessed using standard methods.6,7 The CERC, 
comprising four independent HIV physicians, adju-
dicated event reports against standard prespecified 
diagnostic criteria (stage 3 and 4 events, WHO criteria;8 
serious non-AIDS events, INSIGHT criteria;9 adverse 
events, DAIDS criteria10) and assessed relationship to 
antiretroviral drugs.
Outcomes
The primary endpoint for the 96-week analysis,3 reported 
elsewhere, was a composite endpoint (good disease 
control) based on clinical status through 96 weeks 
(no new WHO stage 4 events after randomisation other 
than oeosophageal candidiasis or mucosal herpes simplex 
virus infection), and CD4 count higher than 250 cells 
per μL, and viral load less than 10 000 copies per mL (or 
>10 000 copies per mL without major or minor protease 
inhibitor resistance mutations) at week 96. The primary 
outcome for the week-144 analysis was viral load of less 
than 400 copies at week 144. Secondary endpoints at week 
144 were viral load of less than 50 copies per mL, viral load 
of less than 1000 copies per mL, protease inhibitor 
resistance mutations, intermediate or high level of 
lopinavir resistance, good disease control, survival, WHO 
stage 4 events, CD4 count greater than 250 cells per μL, 
CD4 count change from baseline, serious adverse events, 
grade 3 or 4 adverse events (all, or ART-related), and 
change in neurocognitive function from baseline.
Statistical analysis
For the sample size calculation, we assumed that 75% of 
patients in the protease inhibitor plus NRTI group would 
have good disease control at week 96 and 10% would be 
lost to follow-up. With a one-sided α of 0·025 for the non-
inferiority comparison and two-sided α of 0·025 for the 
superiority comparison, we estimated that 400 patients 
per group provided 80% power to show non-inferiority 
of protease inhibitor monotherapy using a 10% non-
inferiority mar gin, and 87% power to demonstrate 
superiority of protease inhibitor plus raltegravir assuming 
10% greater response rate.3
All comparisons were according to randomised arm 
(intention-to-treat) regardless of ART changes after 
randomisation. Statistical tests were two-sided and did not 
adjust for multiplicity. 95% CIs correspond to a two-sided 
test for superiority; for non-inferiority comparisons, the 
focus was on the lower confidence limit. The endpoint of 
good disease control used multiple imputations to account 
for missing CD4 cell count, viral loads, and genotypes (<5% 
of observations). Following the statistical analysis plan, the 
primary analysis of all other endpoints used complete-case 
analyses and excluded deaths, individuals lost to follow-up, 
and missed visits. Binary endpoints were compared using 
risk differences and χ² tests, and continuous variables 
using mean change from baseline and t tests or ANOVA. 
Time-to-event endpoints were analysed using Cox 
proportional hazards regression and Kaplan-Meier. 
Generalised estimating equations (independent correlation 
structure, binomial for viral-load suppression and eGFR 
<60 mL/min per 1·73 m², and normal distribution for CD4 
and eGFR change) were used to test difference between 
groups across all visit weeks. Prevalence of intermediate-
high level resistance at week 144 was adjusted for failed or 
missing genotypes using sampling weights.
Of three protocol-specified viral-load thresholds (50, 400, 
and 1000 copies per mL), we selected 400 copies per mL as 
the main outcome because it is less affected by transient, 
low-level viral-load blips, is closest to failure thresholds 
used in most contemporary treatment guidelines (although 
WHO uses a threshold of 1000 copies per mL),2,11–13 and was 
the main outcome reported for viral-load suppression 
analyses at week 96.3 For the protease inhibitor plus NRTI 
versus protease inhibitor plus raltegravir comparison, in 
addition to the primary complete-case analysis, we also did 
several exploratory analyses of virological responses 
commonly used for industry trials, based on modified 
US Food and Drug Administration definitions. A per-
protocol analysis excluded any patient who moved off their 
randomised ART strategy before week 144. A time to loss of 
virological response (TLOVR) analysis assigned an 
outcome of virological failure to those individuals who had 
PI plus NRTI  
(n=426)
PI plus raltegravir 
(n=433)
PI monotherapy 
(n=418)
Sex
Male 162 (38%) 170 (39%) 203 (49%) 
Female 264 (62%) 263 (61%) 215 (51%)
Age (years) 37 (31–43) 37 (30–43) 38 (32–44)
Range 12–73 12–75 12–71
BMI (kg/m²) 20 (18–23) 21 (18–23) 21 (18–23)
Known to be WHO stage 4 85 (20%) 98 (23%) 97 (23%)
CD4 count (cells per μL) 72 (29–143) 70 (27–142) 70 (33–149)
<100 262 (62%) 267 (62%) 258 (62%)
Viral load (copies per mL) 67 515 
(23 065–175 800)
74 500 
(25 004–205 000)
70 874 
(21 584–210 000)
≥100 000 168 (39%) 181 (42%) 181 (43%)
ART history
Years on combination ART 4·0 (2·8–5·4) 4·0 (2·9–5·5) 3·9 (2·6–5·4)
Ever taken as first-line drug
Zidovudine 292 (69%) 283 (65%) 287 (69%)
Stavudine 266 (62%) 266 (61%) 245 (59%)
Tenofovir 52 (12%) 71 (16%) 60 (14%)
Laboratory parameters
Haemoglobin (g/dL) 11·9 (2·2) 11·9 (2·2) 12·0 (2·1)
eGFR (mL/min per 1·73 m2) 114·7 (37·6) 114·8 (39·1) 112·5 (38·0)
Data are n (%), median (IQR), or mean (SD), unless otherwise specified. BMI calculated for 1243 (97%) participants 
with height available (one patient in the PI plus raltegravir group missing weight). WHO stage available for 766 (60%) 
participants: remainder came from other clinics without good previous medical history. Haemoglobin available for 
1268 (99%) participants and eGFR available for 1238 (97%) participants. Additional baseline characteristics have been 
published previously.3 PI=protease inhibitor. NRTI=nucleoside reverse-transcriptase inhibitors. BMI=body-mass index. 
ART=antiretroviral therapy. eGFR=estimated glomerular filtration rate.
Table 1: Baseline characteristics
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no viral loads below the specified threshold up to and 
including week 24 (and had at least two viral loads in this 
period); and those who had confirmed viral load above the 
specified threshold (two consecutive viral loads, using the 
date of the first viral load as time of failure or the date of the 
first missing scheduled viral load after the preceding 
suppressed sample, if the confirmed viral load was 
preceded by missing viral loads), or switched treatment for 
failure (clinical or immunological, confirmed by real-time 
viral-load testing), or who had withdrawn or were lost to 
follow-up or died before week 144 or who had a missing 
viral-load test result at week 144. A snapshot analysis 
assigned an outcome of virological failure to patients who 
had a viral load above the specified threshold at week 144, 
who switched for failure (defined as above), who had 
withdrawn or were lost to follow-up or died before week 144, 
or who had a missing viral-load measure ment at week 144.
Subgroup analyses comparing protease inhibitor plus 
NRTI versus protease inhibitor plus raltegravir groups at 
week 144 were done following the intention-to-treat 
principle, on the complete-case population using the same 
non-inferiority margin of 10% to compare the two 
treatment groups, although we recognise that the power 
to determine non-inferiority is lower within subgroups 
and the trial was not formally powered for this (additional 
details in the appendix p 3). All authors vouch for the 
completeness of the data and analyses presented and 
fidelity of this report to the protocol.
The EARNEST trial is registered with ISRCTN, 
number 37737787.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
PI plus NRTI 
(n=426)
PI plus 
raltegravir 
(n=433)
PI 
monotherapy 
(n=418)
Global 
p value
PI plus raltegravir vs PI plus 
NRTI
PI monotherapy vs PI plus NRTI
Risk difference and HR 
(95% CI)*
p value Risk difference and HR 
(95% CI)*
p value
Viral load (copies per mL)
Available 367 383 375 ·· ·· ·· ·· ··
<50 276 (75%) 275 (72%) 246 (66%) 0·01 –3·4% (–9·7 to 2·9) 0·29 –9·6% (–16·1 to –3·1) 0·004
<400 317 (86%) 312 (81%) 292 (78%) 0·01 –4·9% (–10·2 to 0·3) 0·07 –8·5% (–14·0 to –3·0) 0·003
<1000 321 (87%) 321 (84%) 301 (80%) 0·03 –3·7% (–8·7 to 1·4) 0·15 –7·2% (–12·5 to –1·9) 0·008
Any major or minor PI resistance mutation† 7 (2%) 12 (4%) 32 (11%) <0·0001 1·4% (–1·2 to 4·0) 0·29 8·6% (4·7 to 12·5) <0·0001
Viral load <10 000 copies per mL or no major or 
minor PI resistance mutation/total with viral load
361/367 (98%) 373/383 (97%) 351/375 (94%) 0·001 –1·0% (–3·0 to 1·1) 0·36 –4·8% (–7·6 to 2·0) 0·001
Intermediate/high level LPV/r resistance† 7 (2%) 9 (3%) 31 (11%) <0·0001 0·5% (–1·9 to 2·9) 0·69 8·3% (4·4 to 12·2) <0·0001
Intermediate/high level DRV/r resistance† 1 (<1%) 2 (<1%) 12 (3%) 0·001 0·3% (–0·8 to 1·3) 0·59 3·8% (1·4 to 6·1) 0·002
Intermediate/high level NRTI resistance† 10 (3%) ·· ·· ·· ·· ·· ·· ··
Intermediate/high level raltegravir resistance† ·· 13 (7%) ·· ·· ·· ·· ·· ··
Viral load <400 copies per mL
Per protocol 306/348 (88%) 296/357 (83%) ·· ·· –5·0% (–10·2 to 0·2) 0·06 ·· ··
TLOVR 307/426 (72%) 307/433 (71%) ·· ·· –0·4% (–3·5 to 2·7) 
HR 0·97 (0·75 to 1·24)
0·80 ·· ··
Snapshot 316/426 (74%) 312/433 (72%) ·· ·· –2·1% (–8·1 to 3·8) 0·48 ·· ··
Good disease control‡ 283·6 (67%) 291·9 (67%) 261·8 (63%) 0·31 0·8% (–5·5 to 7·2) 0·80 –3·9% (–10·4 to 2·6) 0·24
Alive 384 (90%) 400 (92%) 387 (93%) 0·37 0·9 (–0·7 to 2·4) 
HR 1·29 (0·82 to 2·04)
0·27 1·0 (–0·5 to 2·5) 
HR 1·34 (0·85 to 2·14)
0·21
Alive with no WHO stage 4§ 368 (86%) 385 (89%) 371 (89%) 0·74 1·4 (–1·4 to 4·1) 
HR 1·07 (0·73 to 1·58)
0·73 1·4 (–1·3 to 4·2) 
HR 1·17 (0·79 to 1·72)
0·44
CD4 count >250 cells per μL 282/366 (77%) 298/385 (77%) 271/377 (72%) 0·15 0·4% (–5·6 to 6·4) 0·91 –5·2% (–11·4 to 1·1) 0·11
CD4 count, mean change 290 (10) 296 (11) 281 (11) 0·61 6 (–23 to 36) 0·66 –8 (–37 to 20) 0·57
Data are n, n (%),n/N (%), or mean (SE), unless otherwise specified. PI=protease inhibitor. NRTI=nucleoside reverse-transcriptase inhibitors. LPV/r=lopinavir plus ritonavir. DRV/r=darunavir plus ritonavir. TLOVR=time 
to loss of virologic response. HR=hazard ratio. p values given at week 144 from χ² tests for binary endpoints, t tests for continuous endpoints, and Cox proportional hazards models for time-to-event endpoints. 
Any major or minor PI resistance mutation is identically equal to any lopinavir resistance by Stanford (potential low, low, intermediate, or high level). Alive includes the 1·5% lost to follow-up and not known to have 
died before week 144. *Absolute risk difference and difference in rate per 100 person-years for binary and time-to-event outcomes (WHO stage 4 or death, death, or TLOVR). HR from Cox proportional hazards model 
also provided for time-to-event outcomes and is for the good outcome. †n is number of observed patients with each outcome based on genotype; percentage is of all patients who had viral load measured, using 
inverse probability weighting within each randomised group to allow for missing genotypes (in 32 [18%] of 182 with viral load >1000 copies per mL); individual NRTI mutations in PI plus NRTI group included zero 
65R, eight 70R, nine 67N, six 215Y, six 41L; 37 TAM2, 21 TAM1, and one 151M; raltegravir mutations in PI plus raltegravir group were three 143R, seven 155H, one 148H and 155H, one 97A (minor), and one 66A and 
97A (minor); PI mutations most commonly observed were 46I/L (major) in six in PI plus NRTI, five in PI plus raltegravir, and 20 in PI monotherapy; 54V (minor) in four in PI plus NRTI, six in PI plus raltegravir, and 
17 in PI monotherapy; 82A/F/S (major) in four in PI plus NRTI, seven in PI plus raltegravir, and 23 in PI monotherapy; 76V (major) in two in PI plus NRTI, four in PI plus raltegravir, and nine in PI monotherapy. 
‡Based on multiple imputation; all other data are as observed (excluding deaths, lost to follow-up, and missed visits). §Excluding oesophageal candidiasis and mucosal herpes simplex virus infections.
Table 2: Viral load, resistance, and main efficacy outcomes at 144 weeks
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the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Between April 12, 2010, and April 29, 2011, 1837 patients 
were screened for eligibility, of whom 1277 patients were 
randomly assigned to an intervention group. 426 patients 
were assigned to protease inhibitor plus NRTI, 433 patients 
were assigned to protease inhibitor plus raltegravir, and 
418 patients were assigned to protease inhibitor mono-
therapy (figure 1); baseline characteristics were similar 
across treatment groups (table 1).3 Patients had advanced 
first-line treatment failure with high viral load (median 
69 782 copies per mL; 530 [42%] of 1277 patients had viral 
loads of >100 000 copies per mL) and low CD4 count 
(median 71 cells per μL; 787 [62%] of 1277 patients had 
counts of <100 cells per μL), and extensive baseline 
resistance (769 [98%] of 787 patients had one or more 
major NRTI mutations).14 In the protease inhibitor plus 
NRTI group, 336 (79%) of 426 patients received tenofovir 
in their initial second-line regimen (all with lamivudine or 
emtricitabine; 37 [9%] patients had zidovudine as a third 
NRTI). By 144 weeks, 106 (8%) of 1277 patients had died, 
30 (2%) had withdrawn or were lost to follow-up, and 
ten (1%, two patients in the protease inhibitor plus NRTI 
group, eight in the protease inhibitor monotherapy group) 
had switched ART due to treatment failure (figure 1).
At week 144, 317 (86%) of 367 participants in the protease 
inhibitor plus NRTI group had viral loads of less than 
400 copies per mL, 276 (75%) had viral loads of less than 
50 copies per mL, and 321 (87%) had viral loads of less 
than 1000 copies per mL (table 2). At week 144, intermediate 
or high-level resistance to one or more NRTIs (excluding 
lamivudine and emtricitabine) taken during the trial was 
seen in ten participants (3% of protease inhibitor plus 
NRTI group overall, adjusting for failed genotypes) and to 
lopinavir in seven patients (2%, one with intermediate-
level cross-resistance to darunavir; table 2).
In the protease inhibitor plus raltegravir group, 
312 (81%) of 383 participants had viral loads of less than 
400 copies per mL, 275 (72%) had viral loads of less than 
50 copies per mL, and 321 (84%) had viral loads of less 
than 1000 copies per mL at week 144 (table 2). Viral-load 
suppression to less than 400 copies per mL was greater 
in the protease inhibitor plus raltegravir group than in 
the protease inhibitor plus NRTI group at week 4 
(p<0·0001; figure 2; appendix p 4), but by week 24 there 
was no evidence of a difference (p=0·19). From week 36 
to week 144, a small, but significant, overall difference 
between the groups initially favoured protease inhibitor 
plus raltegravir and subsequently protease inhibitor plus 
NRTI (p=0·005; figure 2). At week 144, for the primary 
complete-case analysis at less than 400 copies per mL, 
protease inhibitor plus raltegravir was not superior to 
protease inhibitor plus NRTI and did not meet the non-
inferiority criterion (95% lower confidence limit for 
the difference exceeded prespecified 10% margin), but 
was not significantly inferior to protease inhibitor plus 
NRTI (difference –4·9% [95% CI –10·2 to 0·3]; p=0·07; 
table 2, appendix p 6). Similar results were seen with the 
per-protocol analysis (–5·0% [–10·2 to 0·2]; p=0·06; 
Figure 2: Plasma viral load of less than 400 copies per mL to week 144 in the three treatment groups
NRTI=nucleoside reverse-transcriptase inhibitors. GEE=generalised estimating equations. p values comparing the groups by GEE across all weeks from week 36 
onwards (testing any direction of effect): global GEE p<0·0001, protease inhibitor plus raltegravir vs protease inhibitor plus NRTI GEE p=0·005, protease inhibitor 
monotherapy vs protease inhibitor plus NRTI GEE p<0·0001.
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table 2, appendix p 6). Time to loss of virological response 
(rate difference –0·4% [–3·5 to 2·7]; p= 0·80) and 
snapshot analyses (difference –2·1% [–8·1 to 3·8]; 
p=0·48) confirmed that protease inhibitor plus raltegravir 
was not superior to protease inhibitor plus NRTIs, 
although the non-inferiority criterion was met (table 2, 
appendix p 6). Protease inhibitor plus raltegravir did not 
show superiority in any subgroup and did not meet non-
inferiority criteria in many sub groups; there was no 
evidence that its performance relative to protease 
inhibitor plus NRTI varied across any subgroup (figure 3, 
appendix p 7). This pattern of virological outcomes 
between the protease inhibitor plus raltegravir group and 
the protease inhibitor plus NRTI group was generally 
consistent for viral-load suppression at less than 
50 copies per mL (difference –3·4% [95% CI –9·7 to 2·9%]; 
p=0·29) and at less than 1000 copies per mL (–3·7% 
[–8·7 to 1·4]; p=0·15) on complete-case analyses and 
across other secondary analyses (appendix pp 6–10). At 
week 144, intermediate or high-level resistance to 
Figure 3: Plasma viral load of less than 400 copies per mL 144 weeks after switch to second-line by analysis approach and key subgroups
ART=antiretroviral therapy. GSS=genotypic susceptibility score. NRTI=nucleoside reverse-transcriptase inhibitors. PI=protease inhibitor. For all factors or subgroups 
tested see appendix (p 3) and for those not shown here see appendix (p 7).
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Time on first-line ART
   ≤4 years
   >4 years
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Subtype
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152/180 (84%)
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70/98 (71%)
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63/75 (84%)
59/86 (69%)
78/84 (93%)
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  –2·9 (–9·7 to 4·0)
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    6·5 (–17·5 to 30·5)
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  –5·2 (–16·4 to 5·9)
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–12·8 (–29·7 to 4·2)
  –4·2 (–9·8 to 1·4)
  –7·1 (–16·2 to 2·1)
  –5·0 (–11·8 to 1·8)
  –6·3 (–19·1 to 6·4)
  –5·0 (–10·9 to 0·9)
  –5·8 (–16·6 to 5·0)
  –1·2 (–10·0 to 7·7)
  –7·8 (–18·6 to 3·0)
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0·26
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raltegravir was seen in 13 participants (7% of protease 
inhibitor plus raltegravir group overall, adjusting for 
29 failed genotypes) and to lopinavir in nine (3%; two 
with intermediate-level cross-resistance to darunavir; 
table 2). The proportion of patients with intermediate-
high raltegravir resistance in the protease inhibitor plus 
raltegravir group (7%) did not differ significantly from 
the proportion with NRTI resistance in the protease 
inhibitor plus NRTI group (3%; p=0·06).
In the protease inhibitor monotherapy group at 
week 144, 292 (78%) of 375 participants had viral loads 
of less than 400 copies per mL, 246 (66%) had viral 
loads of less than 50 copies per mL and 301 (80%) had 
viral load of less than 1000 copies per mL (table 2). In 
protease inhibitor monotherapy, viral-load suppression 
at less than 400 copies per mL decreased progressively 
from week 12 (when raltegravir was discontinued) to 
week 96 (figure 2) and increased at week 144 after 
the data monitoring committee recommendation to 
resume combination therapy (difference –8·5% 
[95% CI –14·0 to –3·0]; p=0·003 vs protease inhibitor 
plus NRTI at week 144). Intermediate or high-level 
resistance to lopinavir was seen in 31 participants (11%; 
12 patients had intermediate-level cross-resistance to 
darunavir).
There was no difference between the three randomised 
groups at week 144 in the proportions of patients 
with good disease control (composite endpoint used for 
primary week 96 comparison), who were alive, were alive 
without new WHO stage 4 events, or who had CD4 
counts of more than 250 cells per μL (table 2); or in mean 
CD4 change from baseline (p=0·11 across all timepoints, 
appendix p 11).
There was no difference between the groups in serious 
adverse events (global p=0·63), grade 3 or 4 adverse 
events (total [global p=0·93], or ART-related [global 
p=0·12]), or events that resulted in treatment modification 
(global p=0·06; table 3, appendix p 5). In the protease 
PI plus NRTI 
(n=426)
PI plus raltegravir 
(n=433)
PI monotherapy 
(n=418)
Global 
p value
PI plus raltegravir vs PI plus NRTI PI monotherapy vs PI plus NRTI
Risk difference and HR* 
(95% CI)
p value Risk difference and HR* 
(95% CI)
p value
Serious adverse events 113 (27%) 106 (24%) 99 (24%) 0·63 –0·9 (–3·9 to 2·1) 
HR 0·93 (0·71 to 1·21)
0·57 –1·5 (–4·4 to 1·5) 
HR 0·88 (0·67 to 1·15)
0·34
Total number of events 139 127 131 ·· ·· ·· ·· ··
Grade 3 or 4 events 117 (27%) 118 (27%) 119 (28%) 0·93 0·2 (–2·9 to 3·4) 
HR 1·02 (0·79 to 1·31)
0·89 0·7 (–2·5 to 3·9) 
HR 1·05 (0·81 to 1·35)
0·72
Total grade 3 or 4 events 177 171 161 ·· ·· ·· ·· ··
Cardiovascular 3 5 7 ·· ·· ·· ·· ··
Respiratory 36 35 32 ·· ·· ·· ·· ··
Gastrointestinal 15 13 13 ·· ·· ·· ·· ··
Hepatic 4 9 6 ·· ·· ·· ·· ··
Renal 9 8 5 ·· ·· ·· ·· ··
Central nervous system 19 17 21 ·· ·· ·· ·· ··
Skin 6 12 6 ·· ·· ·· ·· ··
Haematological 17 12 9 ·· ·· ·· ·· ··
Other 68 60 62 ·· ·· ·· ·· ··
Grade 3 or 4 events possibly, probably, 
or definitely ART-related†
26 (6%) 22 (5%) 13 (3%) 0·12 –0·4 (–1·7 to 0·9) 
HR 0·84 (0·47 to 1·48)
0·54 –1·2 (–2·4 to –0·1) 
HR 0·50 (0·26 to 0·98)
0·04
Total events 29 24 14 ·· ·· ·· ·· ··
Adverse events resulting in 
ART-modification
25 (6%) 22 (5%) 11 (3%) 0·06 –0·3 (–1·5 to 1·0) 0·66 –1·3 (–2·4 to –2·1) 0·02
Haemoglobin g/dL, mean change‡ 1·2 (0·1) 1·2 (0·1) 1·3 (0·1) 0·73 0·0 (–0·3 to 0·3) 0·88 0·1 (–0·2 to 0·4) 0·47
eGFR mL/min per 1·73 m²‡
Mean change –12·6 (2·0) –7·8 (1·8) –8·8 (1·8) 0·16 4·8 (–0·4 to 10·1) 0·07 3·8 (–1·4 to 9·1) 0·15
eGFR<60 23/368 (6%) 20/384 (5%) 22/375 (6%) 0·83 –1·0% (–4·4 to 2·3) 0·54 –0·4% (–3·8 to 3·0) 0·83
Neurocognitive Z score, mean change‡ 1·43 (0·08) 1·42 (0·08) 1·38 (0·08) 0·89 –0·00 (–0·22 to 0·21) 0·98 –0·05 (–0·28 to 0·18) 0·67
Peripheral neuropathy (symptomatic)‡ 52/367 (14%) 66/383 (17%) 63/371 (17%) 0·45 3·1% (–2·1 to 8·3) 0·25 2·8 (–2·4 to 8·0) 0·29
Data are n (%), n, mean (SE), or n/N (%), unless otherwise specified. Table shows number of patients who had a particular category of event followed by the total number of events in that category (a patient 
might have more than one event). PI=protease inhibitor. NRTI=nucleoside reverse-transcriptase inhibitor. ART=antiretroviral therapy. HR=hazard ratio. eGFR=estimated glomerular filtration. p values given at 
week 144 from χ² tests for binary endpoints, t tests for continuous endpoints, and Cox proportional hazards models for time-to-event endpoints. Cockroft-Gault equation was used for eGFR. *Absolute risk 
difference for binary outcomes and difference in rate per 100 person-years for time-to-event outcomes (serious adverse events and grade 3 or 4 adverse events). HR from Cox proportional hazards model also 
provided for time-to-event outcomes. †Assessed by the clinical expert review committee. ‡At week 144.
Table 3: Safety outcomes to week 144
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inhibitor plus NRTI group, five patients changed ART 
because of renal adverse events (two had acute renal 
failure; both with tenofovir) and five patients changed 
ART because of haematological adverse events (four had 
anaemia, one had neutropenia; all with zidovudine). 
There was no difference between the groups at week 144 
in estimated glomerular filtration rate (eGFR) changes 
from baseline (global p=0·16; appendix p 12), proportions 
with eGFR of less than 60 ml/min per 1·73 m² 
(global p=0·83; appendix p 12), haemoglobin changes 
from baseline (global p=0·73), neurocognitive function 
changes from baseline (global p=0·89) or proportions 
with peripheral neuropathy (global p=0·45; table 3).
Discussion
Our findings from this trial, the largest randomised 
controlled trial of second-line therapy and the only one 
with 144 weeks’ follow-up, show that the robust response 
we reported previously3 in the protease inhibitor plus 
NRTI group at week 96 is durable, with high rates of viral-
load suppression and low rates of drug resistance at 144 
weeks. The response was not impaired by the extensive 
baseline NRTI cross-resistance present in these patients, 
as discussed elsewhere.15 The regimen was also well 
tolerated. Although most patients who were on protease 
inhibitor plus NRTI received tenofovir-containing 
regimens and we used sparse renal toxicity monitoring 
(achievable in typical programme settings), few patients 
developed clinically significant renal toxicity. This finding 
is consistent with reports from similar African 
programme settings,16,17 and shows that intensive renal 
monitoring is unnecessary in the public health approach 
in Africa, even in second-line therapy in which serum 
concentrations of tenofovir are boosted by concomitant 
protease inhibitor use. More data are needed in Asian 
patients in whom lower average bodyweight might 
further increase tenofovir concentrations. A recently 
licensed pro-drug of tenofovir, tenofovir–alafenamide, 
has toxicity advantages over the conventional formulation, 
including lower renal toxicity.18 However, based on our 
data, sparing renal toxicity does not provide a compelling 
argument for its large-scale adoption in African 
programmes following the public health approach 
(although others might exist). Also encouragingly, we 
found minimal cross-resistance to darunavir after 
144 weeks using a lopinavir-based, second-line regimen, 
which supports the recommended sequence of using 
lopinavir (combined with NRTIs) for second-line therapy 
and retaining darunavir for use in third-line therapy, 
especially as the only trial comparing darunavir with 
lopinavir in second-line therapy did not show non-
inferiority of darunavir.19
The original hypothesis underlying this trial was that 
protease inhibitor plus raltegravir, comprising two new 
drug classes expected to be fully active, would be superior 
to protease inhibitor plus NRTI as second-line therapy. 
However, we found no evidence of virological superiority 
of protease inhibitor plus raltegravir at 144 weeks in either 
the primary (complete-case) approach or multiple 
secondary analyses, consistent with previously reported 
findings at 48–96 weeks from EARNEST and other 
trials.3–5 These earlier reports established non-inferiority 
of protease inhibitor plus raltegravir, but our findings at 
week 144 are more equivocal: non-inferiority criteria 
versus protease inhibitor plus NRTI were not met in the 
complete-case and per-protocol analysis of viral-load 
suppression, although the 95% CI lay only marginally 
outside the specified 10% non-inferiority margin. The 
protease inhibitor plus raltegravir group did meet non-
inferiority criteria on analyses using other viral-load 
thresholds (50 copies per mL and 1000 copies per mL) 
and using approaches (TLOVR and snapshot) that 
counted death as viological failure. This difference 
between analyses that counted death as virological failure 
and the complete case and per-protocol analysis, which 
did not, was primarily because mortality was 2% greater 
in protease inhibitor plus NRTI, which abrogated the 
small virological difference favouring protease inhibitor 
plus NRTI. This small mortality diff erence between the 
groups might be a chance finding unrelated to the 
randomised treatment allocation (it is not statistically 
significant) and to underlying virological efficacy 
(the death rate was similar in the protease inhibitor 
monotherapy group even though virological control was 
markedly worse). Different analysis ap proaches 
sometimes yield contrasting conclusions regarding non-
inferiority, but a confident assertion of non-inferiority 
usually requires consistent results across all analyses: 
such consistency was not observed.
The explanation for these unexpected findings (absence 
of virological superiority of protease inhibitor plus 
raltegravir and inability to demonstrate consistent non-
inferiority of this regimen) is unclear, but pharmacokinetic 
factors might have an important role. Raltegravir has a 
low genetic barrier to resistance and relatively short half-
life and might therefore be more susceptible to the 
development of resistance during episodes of non-
adherence compared with tenofovir, which has a moder-
ate genetic barrier and long intracellular half-life.20–22 
Higher rates of resistance to raltegravir compared with 
NRTIs observed at week 144 are also consistent with 
greater fragility of this regimen (although the difference 
was not statistically significant). Trials of protease 
inhibitor plus raltegravir combinations in first-line 
therapy have also shown good virological suppression 
overall, but less impressive performance in those with 
high viral load and low CD4 count.23–25 Although adverse 
event rates were low with this regimen, we found no 
evidence of a safety benefit to raltegravir compared with 
NRTIs in second-line therapy. Dolutegravir, an alternative 
drug in the integrase strand transfer inhibitor class, 
which has a higher genetic barrier to resistance and a 
longer half-life than raltegravir, might be a better 
candidate for use in combination with a protease inhibitor 
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or NRTIs for second-line therapy in resource-limited 
settings.26,27 24-week interim data from a trial28 comparing 
a dolutegravir plus NRTI regimen with a standard-of care 
protease inhibitor plus NRTI regimen in second-line 
therapy suggest virological superiority of the dolutegravir-
containing regimen. However, the trial was done in 
middle-income countries, with a requirement for 
resistance testing and selection of patients who had at 
least one fully active NRTI in the second-line regimen, 
which limit generalisability to the more challenging 
situation of low-income countries following the public 
health approach. Importantly, most participants in 
EARNEST had no fully active NRTIs in their second-line 
regimen.15 Notably, the restoration of suppression in the 
protease inhibitor monotherapy group with reintroduction 
of combination therapy (mainly NRTIs) after week 96 
confirms the contribution that NRTIs make to the 
virological efficacy of a protease inhibitor-based regimen, 
even when their activity is predicted to be substantially, or 
even completely, compromised by cross-resistance.
The strengths of this trial are its size, follow-up 
duration, low withdrawal or loss to follow-up, and regular 
storage of samples for subsequent centralised viral-load 
and resistance testing. The broad eligibility criteria and 
pragmatic approach to delivering treatment (predom-
inantly nurse-led care, clinician drug selection without 
resistance testing, clinical and immunological efficacy 
monitoring, sparse laboratory safety monitoring) all 
enhance generalisability to programme settings in which 
most patients receive second-line ART, and viral-load 
testing remains challenging and resistance testing is 
rarely available.
The main limitation of this study is that treatment was 
given open-label (which was necessary because it was a 
pragmatic strategy trial with clinician-selected NRTIs); 
however, very few patients changed from their allocated 
treatment strategy and the main outcomes were laboratory 
parameters assayed blind to treatment received. Most 
patients were taking a zidovudine or stavudine-based 
NRTI regimen first-line, and switched to tenofovir at the 
start of second-line therapy. Current WHO guidelines 
indicate tenofovir is preferred in first-line, with switch to 
zidovudine for second-line. However, the virological 
efficacy of the second-line protease inhibitor plus NRTI 
regimen does not appear to depend on activity of particular 
NRTIs, so it is unlikely that this difference in the sequence 
of NRTIs used would have a substantial impact on our 
results.15
Our findings have important implications for the 
selection of regimens for second-line therapy in the public 
health approach. The good longer-term outcomes with the 
combination of a protease inhibitor (in this case lopinavir) 
with two NRTIs provides support for this regimen as the 
WHO-recommended preferred second-line combination.2 
Dolutegravir might replace efavirenz as standardised first-
line therapy in the public health approach in the future, 
but this should not affect the efficacy of second-line 
protease inhibitor plus NRTI. Our observations with this 
regimen are therefore likely to remain relevant for the 
foreseeable future. Although the protease inhibitor plus 
raltegravir regimen is currently recommended by WHO 
as an alternative second-line regimen,2 our findings with 
this combination (absence of virological advantage overall 
or in any subgroup tested, failure to show non-inferiority 
consistently across all analyses, absence of a substantive 
toxicity advantage) taken together with the higher cost of 
raltegravir, indicate there is no compelling reason for 
national programmes to adopt this as the standardised 
second-line therapy.
In settings where therapy can be individualised, a 
protease inhibitor plus raltegravir regimen could be of 
value in selected patients if used with regular virological 
monitoring and adjusted (with drug substitutions) as 
needed. In the public health approach, a decision to 
change the standardised sequence of regimens will affect 
millions of people, and the consequences of an 
underperforming regimen might not be easily detected 
and reversed at an individual level. This trial, with its 
unexpected outcomes, reinforces the need for robust 
randomised trials with substantial long-term follow-up to 
be done in resource-limited settings in the populations 
in whom the public health approach is used before 
recommendations are changed.
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